WTR Insights Conference Preview: Nurexone's Nerve Regeneration & Anixa's Cancer Immunotherapy in Focus

In this special preview episode of WTR Healthcare Happenings, Robert Sassoon spotlights two biotechs presenting on Day 1 of the WTR Insights Conference (April 14–15). Nurexone Biologic (TSX-V: NRX | OTCQB: NRXBF) is pioneering an exosome-based therapy for spinal cord injury and other CNS conditions, with Phase 1/2A trials expected to initiate within 12 months. Anixa Biosciences (NASDAQ: ANIX) is advancing a breast cancer vaccine and a novel CAR-T therapy for ovarian cancer — both approaching key clinical inflection points in 2026.  Complimentary for Investors. Register at WaterTowerResearch.com.